Abstract
Introduction Traditional thoracic endovascular aortic repair (TEVAR) relies on distal landing zones beyond the left common carotid artery, which may underperform in patients with complex aortic anatomy. The Nexus Aortic Arch Stent Graft enables proximal landing zones in the ascending aorta, expanding endovascular options for challenging arch pathology. This study applies a geometrically focused framework using fluctuation in total integrated Gaussian curvature (δK), a size-invariant metric of surface topology, to evaluate Nexus performance across diverse aortic morphologies.
Methods Pre-operative CT imaging was analyzed for 27 patients treated with the Nexus device and 37 treated with traditional TEVAR (proximal landing zones 2/3). CT scans from 215 patients with non-pathologic aortas served as controls. Two-dimensional aortic surface meshes were constructed to calculate δK and mean aortic radius, while tortuosity index was derived from the centerline. Nexus data were mapped into a previously established size-shape feature space to assess predicted outcomes. TEVAR failure was defined as reintervention or death due to aneurysmal growth, endoleak, dissection extension, or rupture. Correlation and clustering analyses evaluated relationships between aortic morphology and outcomes. A scale-sampling approach captured the multiscale nature of aortic geometry while reducing sensitivity to mesh resolution and partitioning.
Results The Traditional TEVAR cohort had a significantly lower success rate than the Nexus cohort (51.4% vs. 85.2%, p = 0.005). Traditional TEVAR was particularly less effective in patients with elevated δK and large mean radius, whereas the Nexus device demonstrated favorable outcomes even in anatomically complex aortas with similarly elevated δK and radius values. Combining δK and radius demonstrated distinct clustering patterns by pathology: 78.3% of chronic dissections occupied the high δK/radius zone, while 70.6% of isolated aneurysms fell in the low δK/radius zone (p <0.001). δK provided unique morphological insight beyond size, whereas tortuosity index was less discriminative.
Conclusion δK offers a quantitative framework for assessing device performance across variable aortic anatomy. Endovascular arch repair using proximal ascending aortic landing zones, exemplified by the Nexus device, may provide a viable option in patients with complex geometry. This shape-size framework represents a step toward personalized patient selection and improved long-term outcomes.
Competing Interest Statement
Luka Pocivavsek reports financial support was provided by National Heart Lung and Blood Institute. Ian McDougall reports a relationship with Endospan, Ltd. that includes: employment and equity or stocks. Ross Milner reports a relationship with Endospan, Ltd. that includes: consulting or advisory. Endospan, Ltd., provided the data for analysis and helped in providing context of our findings within their prior published trial results. There was no direct financial support for this project from Endospan.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of Chicago gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors





